Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 28 2022 - 10:15AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2022
Commission File Number 001-15170
| GlaxoSmithKline plc |
| (Translation of registrant's name into English) |
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 28 February 2022, London UK
GSK provides further update on phase III RSV maternal vaccine candidate programme
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that, further to the voluntary pause shared on February 18, the Company has decided to stop enrolment and vaccination in trials evaluating its potential respiratory syncytial virus (RSV) maternal vaccine candidate in pregnant women (NCT04605159, NCT04980391, NCT05229068).
Further analysis to better understand safety data from these trials is ongoing, and the relevant regulatory authorities have been informed.
This decision does not impact the ongoing AReSVi 006 phase III trial (NCT04886596) for RSV older adults (60 years and above). This trial remains on track with an anticipated data readout in the first half of 2022.
About GSK
GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us.
| GSK enquiries: | | | |
| Media enquiries: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
| Simon Moore | +44 (0) 20 8047 5502 | (London) |
| Kristen Neese | +1 804 217 8147 | (Philadelphia) |
| Kathleen Quinn | +1 202 603 5003 | (Washington DC) |
| Evan Berland | +1 215 432 0234 | (Philadelphia) |
| | | |
| Analyst/Investor enquiries: | Nick Stone | +44 (0) 7717 618834 | (London) |
| Sonya Ghobrial | +44 (0) 7392 784784 | (Consumer) |
| James Dodwell | +44 (0) 20 8047 2406 | (London) |
| Mick Readey | +44 (0) 7990 339653 | (London) |
| Josh Williams | +44 (0) 7385 415719 | (London) |
| Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
| Frannie DeFranco | +1 215 751 4855 | (Philadelphia) |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK's 2021 Q4 Results and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| | GlaxoSmithKline plc | |
| | (Registrant) | |
| | | | |
| Date: February 28, 2022 | | | |
| | | | |
| | By: | /s/ VICTORIA WHYTE | |
| | | Victoria Whyte | |
| | | Authorised Signatory for and on | |
| | | behalf of GlaxoSmithKline plc | |
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
